Medtronic (MDT) Reports In-Line Q3 EPS; Guides Q4 In-Line

Medtronic (NYSE: MDT) reported Q3 EPS of $1.37, in-line with the analyst estimate of $1.37. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.94 billion.

GUIDANCE:

Medtronic sees Q4 2022 EPS of $1.56-$1.58, versus the consensus of $1.58. The company expects fourth quarter organic revenue growth of approximately 5.5%, in line with current fourth quarter organic revenue growth Street consensus.

For earnings history and earnings-related data on Medtronic (MDT) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c